Published in Am J Med on December 01, 2012
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells. Ann Am Thorac Soc (2014) 1.00
Transforming growth factor-β1 and tumor necrosis factor-α are associated with clinical severity and airflow limitation of COPD in an additive manner. Lung (2013) 0.89
Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One (2014) 0.88
Airway Remodeling in Chronic Obstructive Pulmonary Disease and Asthma: the Role of Matrix Metalloproteinase-9. Arch Immunol Ther Exp (Warsz) (2015) 0.86
Prostanoid receptor EP2 as a therapeutic target. J Med Chem (2013) 0.86
A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases. Br J Pharmacol (2014) 0.81
Effects and mechanism of bufei yishen formula in a rat chronic obstructive pulmonary disease model. Evid Based Complement Alternat Med (2014) 0.79
Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res (2015) 0.78
Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients. Lung (2015) 0.78
Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter. Drug Des Devel Ther (2015) 0.78
MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction. PLoS One (2016) 0.76
Gender difference in plasma fatty-acid-binding protein 4 levels in patients with chronic obstructive pulmonary disease. Biosci Rep (2016) 0.76
Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis (2015) 0.76
Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev (2015) 0.76
Anti-inflammatory effect of Yu-Ping-Feng-San via TGF-β1 signaling suppression in rat model of COPD. Iran J Basic Med Sci (2016) 0.75
Alteration of spontaneous brain activity in COPD patients. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People - Data from the Berlin Aging Study II. PLoS One (2015) 0.75
Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenzae. Sci Rep (2017) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol (2004) 8.70
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol (2006) 4.80
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med (2006) 3.30
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med (2006) 3.30
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther (2005) 2.04
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
Clinical practice guideline: Otitis media with effusion. Otolaryngol Head Neck Surg (2004) 1.98
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol (2007) 1.92
Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am J Med (2004) 1.76
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med (2010) 1.66
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD (2008) 1.65
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc (2007) 1.56
Underestimation of liver-related mortality in the United States. Gastroenterology (2013) 1.46
Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation (2003) 1.42
Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. Respir Med (2004) 1.37
Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest (2006) 1.30
Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha to reduce acute lung inflammation and injury in mice. J Immunol (2009) 1.30
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. J Clin Invest (2013) 1.29
The ecology of medical care for children in the United States. Pediatrics (2003) 1.29
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Development and initial testing of a new socioeconomic status measure based on housing data. J Urban Health (2011) 1.27
Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res (2013) 1.26
Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res (2010) 1.26
Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med (2011) 1.26
Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J Clin Invest (2014) 1.23
A two-county comparison of the HOUSES index on predicting self-rated health. J Epidemiol Community Health (2010) 1.17
Shotgun proteomic analysis of human-induced sputum. Proteomics (2006) 1.16
Measuring the effects of COPD on the patient. Respir Med (2005) 1.13
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med (2013) 1.12
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J (2013) 1.12
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax (2007) 1.12
Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS One (2011) 1.11
Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J (2011) 1.07
The COPD Biomarker Qualification Consortium (CBQC). COPD (2013) 1.06
Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells. Am J Respir Cell Mol Biol (2006) 1.04
The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. J Biol Chem (2007) 1.03
Determinants of patient satisfaction in chronic illness. Arthritis Rheum (2002) 1.02
Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol (2003) 1.02
Recent advances in dyspnea. Chest (2015) 0.99
How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.97
Incidence, secular trends, and outcomes of prosthetic joint infection: a population-based study, olmsted county, Minnesota, 1969-2007. Infect Control Hosp Epidemiol (2012) 0.97
Innovations to achieve excellence in COPD diagnosis and treatment in primary care. Postgrad Med (2010) 0.96
Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J Immunol (2013) 0.96
NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract. Respir Res (2008) 0.96
Selenoprotein N deficiency in mice is associated with abnormal lung development. FASEB J (2013) 0.95
Control of Allergic Rhinitis and Asthma Test (CARAT): dissemination and applications in primary care. Prim Care Respir J (2013) 0.95
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.94
Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.94
Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest (2004) 0.94
Diet and vitamin D as risk factors for lung impairment and COPD. Transl Res (2013) 0.94
How to read the new recommendation statement: methods update from the U.S. Preventive Services Task Force. Ann Intern Med (2007) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. COPD (2013) 0.92
Specialty differences in prescribing inhaled corticosteroids for children. Clin Pediatr (Phila) (2007) 0.92
The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States. Ann Allergy Asthma Immunol (2012) 0.91
Genetically manipulated mouse models of lung disease: potential and pitfalls. Am J Physiol Lung Cell Mol Physiol (2011) 0.90
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res (2008) 0.89
Innovations in lung volume reduction: the non-cutting edge. Chest (2004) 0.89
Increased risk of herpes zoster in children with asthma: a population-based case-control study. J Pediatr (2013) 0.88
One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD (2013) 0.88
The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res (2014) 0.88
ADAM8: a new therapeutic target for asthma. Expert Opin Ther Targets (2009) 0.86
ADAM-33 surfaces as an asthma gene. N Engl J Med (2002) 0.86
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med (2011) 0.86
Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J (2009) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Adam8 limits the development of allergic airway inflammation in mice. J Immunol (2013) 0.84
Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir Med (2013) 0.84
Matrix metalloproteinases: all the RAGE in the acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2011) 0.82
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs (2014) 0.82
Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD (2011) 0.81
Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria. Prim Care Respir J (2012) 0.81
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J (2013) 0.81
Otitis media with effusion clinical practice guideline. Am Fam Physician (2004) 0.80
Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Syst Biol (2014) 0.80
Increasing availability to and ascertaining value of asthma action plans in schools through use of technology and community collaboration. J Sch Health (2013) 0.79
The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Rev Respir Med (2013) 0.78
Therapeutic options for reducing sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis. Curr Med Res Opin (2007) 0.78
Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest (2009) 0.78
Functional characterization of polymorphisms in the peptidase inhibitor 3 (elafin) gene and validation of their contribution to risk of acute respiratory distress syndrome. Am J Respir Cell Mol Biol (2014) 0.77
Interleukin-18: the master regulator driving destructive and remodeling processes in the lungs of patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med (2012) 0.77
Comparison of parent and student responses to asthma surveys: 2 different experiences with similar results. J Sch Health (2006) 0.77
Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest (2008) 0.77
Effects of sex hormones on bronchial reactivity during the menstrual cycle. BMC Pulm Med (2014) 0.77
Prospective Use of Descriptors of Dyspnea to Diagnose Common Respiratory Diseases. Chest (2015) 0.77
Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants. J Pediatr Endocrinol Metab (2015) 0.76
Effects of respiratory cycle and body position on quantitative pulmonary perfusion by MRI. J Magn Reson Imaging (2011) 0.76
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest (2014) 0.76